Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christof Fellmann

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Nature Communications|September 28, 2021
Comprehensive deletion landscape of CRISPR-Cas9 identifies minimal RNA-guided DNA-binding modulesArik Shams, Sean A Higgins, Christof Fellmann, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 24, 2021
Cancer-specific loss of <i>TERT</i> activation sensitizes glioblastoma to DNA damageAlexandra M Amen, Christof Fellmann, Katarzyna M Soczek, et al.
Cancer Cell|April 22, 2014
Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumorsPiro Lito, Anna Saborowski, Jingyin Yue, et al.
Scientific Reports|July 2, 2025
Engineered microRNA scaffolds for potent gene silencing in vivoGiuseppe Militello, Alyssa Greig, Chongfeng Bi, et al.
Cancer Discovery|August 8, 2014
Development of siRNA payloads to target KRAS-mutant cancerTina L Yuan, Christof Fellmann, Chih-Shia Lee, et al.
ACS Central Science|October 1, 2020
Site-Specific Bioconjugation through Enzyme-Catalyzed Tyrosine-Cysteine Bond FormationMarco J Lobba, Christof Fellmann, Alan M Marmelstein, et al.
Developmental Cell|May 13, 2021
PI5P4Ks drive metabolic homeostasis through peroxisome-mitochondria interplayArchna Ravi, Lavinia Palamiuc, Ryan M Loughran, et al.
Genes & Development|August 11, 2011
An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenanceJohannes Zuber, Amy R Rappaport, Weijun Luo, et al.
Elife|August 10, 2019
Structural basis for AcrVA4 inhibition of specific CRISPR-Cas12aGavin J Knott, Brady F Cress, Jun-Jie Liu, et al.
Nature Communications|May 11, 2019
Controlling CRISPR-Cas9 with ligand-activated and ligand-deactivated sgRNAsKale Kundert, James E Lucas, Kyle E Watters, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Nature Communications|September 28, 2021
Comprehensive deletion landscape of CRISPR-Cas9 identifies minimal RNA-guided DNA-binding modulesArik Shams, Sean A Higgins, Christof Fellmann, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 24, 2021
Cancer-specific loss of <i>TERT</i> activation sensitizes glioblastoma to DNA damageAlexandra M Amen, Christof Fellmann, Katarzyna M Soczek, et al.
Cancer Cell|April 22, 2014
Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumorsPiro Lito, Anna Saborowski, Jingyin Yue, et al.
Scientific Reports|July 2, 2025
Engineered microRNA scaffolds for potent gene silencing in vivoGiuseppe Militello, Alyssa Greig, Chongfeng Bi, et al.
Cancer Discovery|August 8, 2014
Development of siRNA payloads to target KRAS-mutant cancerTina L Yuan, Christof Fellmann, Chih-Shia Lee, et al.
ACS Central Science|October 1, 2020
Site-Specific Bioconjugation through Enzyme-Catalyzed Tyrosine-Cysteine Bond FormationMarco J Lobba, Christof Fellmann, Alan M Marmelstein, et al.
Developmental Cell|May 13, 2021
PI5P4Ks drive metabolic homeostasis through peroxisome-mitochondria interplayArchna Ravi, Lavinia Palamiuc, Ryan M Loughran, et al.
Genes & Development|August 11, 2011
An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenanceJohannes Zuber, Amy R Rappaport, Weijun Luo, et al.
Elife|August 10, 2019
Structural basis for AcrVA4 inhibition of specific CRISPR-Cas12aGavin J Knott, Brady F Cress, Jun-Jie Liu, et al.
Nature Communications|May 11, 2019
Controlling CRISPR-Cas9 with ligand-activated and ligand-deactivated sgRNAsKale Kundert, James E Lucas, Kyle E Watters, et al.
Pageof 4